Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
about
Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus InfectionIntermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk.Taxane-induced arthralgia and myalgia: A literature review.C-Terminal Farnesylation of UCH-L1 Plays a Role in Transport of Epstein-Barr Virus Primary Oncoprotein LMP1 to Exosomes.Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice.Recent Advances in the Treatment of Breast Cancer.
P2860
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Phase I study of lonafarnib (S ...... ast cancer: EORTC study 16023.
@en
Phase I study of lonafarnib
@nl
type
label
Phase I study of lonafarnib (S ...... ast cancer: EORTC study 16023.
@en
Phase I study of lonafarnib
@nl
prefLabel
Phase I study of lonafarnib (S ...... ast cancer: EORTC study 16023.
@en
Phase I study of lonafarnib
@nl
P2093
P2860
P1476
Phase I study of lonafarnib (S ...... ast cancer: EORTC study 16023.
@en
P2093
Ahmad Awada
Alwin D R Huitema
Anne-Sophie Govaerts
Bojana Milojkovic Kerklaan
Christophe Le Tourneau
Hilde Rosing
Jan H M Schellens
Jos H Beijnen
Marja Mergui-Roelvink
Martine J Piccart-Gebhart
P2860
P2888
P356
10.1007/S00280-012-1972-1
P577
2012-09-29T00:00:00Z